GlassScriptPhysician profile
Umama Sadia
NPI 1780090233
$4,135.90
in general payments reported to CMS, 2019-2025
40 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.26 · 2021: $287 · 2022: $1,813 · 2023: $1,124 · 2024: $467 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $423.90 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $403.14 | 2019-2025 | Linzess, Creon, Qulipta |
| Bausch Health US, LLC | $364.78 | 2022-2023 | Aplenzin, Wellbutrin |
| Glaxosmithkline, LLC. | $335.46 | 2021-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $206.34 | 2021-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $193.83 | 2021-2023 | Trintellix |
| Novo Nordisk INC | $189.23 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $183.18 | 2022 | |
| Viiv Healthcare Company | $176.15 | 2022-2023 | Apretude |
| Daiichi Sankyo INC. | $168.17 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.22 | 2022-2023 | Xifaxan, Trulance |
| Pfizer INC. | $136.26 | 2023-2025 | |
| Amgen INC. | $118.28 | 2021-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $114.29 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $112.84 | 2022-2023 | Mounjaro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umama Sadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.